Source: Annual Congress 2002 - Acute exacerbations of COPD: aetiology and therapy
Disease area: Airway diseases

Abstract

The MOSAIC is a multinational, double-blind study comparing the effectiveness of a 5-day oral moxifloxacin (MXF) course to that of a 7-day standard oral antibiotic regimen (amoxicillin, clarithromycin or cefuroxime-axetil), in the treatment of AECB.
CB patients with history of smoking and recurrent AECB episodes, were enrolled into the study and their infection-free baseline prospectively established. After stratification with respect to corticosteroids administration, patients were randomised into two parallel groups (MXF or comparator) if they suffered a type 1 Anthonisen AECB episode. Clinical response was assessed 7-10 days post-treatment. The time to regain the pre-exacerbation status was also evaluated as well as the time until next AECB, throughout a 9-month follow-up period.
1935 patients were enrolled. After a 12-month monitoring period, 733 patients had an exacerbation and were randomised.
Duration of CB and number of previous AECB episodes were found to be predictive factors for the occurrence of type 1 AECB episode in this CB population.
Characteristics patients are summarised below:

	Recruited	Randomised	p-value
Age (years)	63.4	63.2	0.64
Sex (%males)	68.2	67.9	0.84
Duration of CB at enrolment (years)	11.7	12.5	0.04
AECB episodes in last year	2.9	3.1	0.0008
FEV1 (% pred)	53.7	54.2	0.58

Rating:

Share or cite this content

Citations should be made in the following way:
R. Wilson, P. Jones, T. Schaberg, P. Davey, L. Allegra, J. L. Izquierdo, P. Arvis, I. Duprat Lomon, M. A. Le Berre, G. Huchon (London, Dundee, United Kingdom; Rotenburg, Germany; Milan, Italy; Guadalajara, Spain; Puteaux, Paris, France). A clinical and outcomes assessment of the management of acute episodes of chronic bronchitis (AECB) : the MOSAIC study - baseline characteristics of screened patients. Eur Respir J 2002; 20: Suppl. 38, 3371

Member's Comments

No comment yet.

Related content which might interest you: Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort. Source: International Congress 2017 – Markers of COPD progression Year: 2017 Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study Source: Annual Congress 2011 - COPD management Year: 2011 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Baseline demographic and clinical profile of patients with and without cardiovascular diseases in the assessment of comorbidities in COPD in european symptomatic subjects from primary care (ACCESS) study Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013 The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 A retrospective cohort study demonstrating the impact of an OPEP device on exacerbations in COPD patients with chronic bronchitis Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS) Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 Comparison of patient-reported outcomes (PROs) during acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 Study of clinical presentation and predictors of adverse outcome in patients admitted for acute exacerbation of COPD. Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 One year experience with acute COPD assessment service (ACAS) for patients with acute exacerbations of COPD Source: Eur Respir J 2006; 28: Suppl. 50, 178s Year: 2006 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Acute exacerbation of COPD patients therapy priorities: A survey study Source: Virtual Congress 2021 – New approaches to pulmonary rehabilitation and chronic care Year: 2021 Procalcitonin-guided assessment of bacterial etiological role in patients admitted for severe COPD exacerbations: a double-blind study Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study Source: Eur Respir J, 58 (6) 2004474; 10.1183/13993003.04474-2020 Year: 2021 Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. A comparative syudy Source: Annual Congress 2013 –COPD mechanisms Year: 2013 ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations Source: Guideline 2022 Year: 2021